MedTrace Logo

Study In Patients With Kidney Cancer Treated With Sutent

NCT00873210 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 121

Last updated 2012-11-09

No results posted yet for this study

Summary

Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.

Conditions

  • Advanced or Metastatic Renal Cell Carcinoma
  • Renal Cancer

Interventions

DRUG

Sutent

50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00873210 on ClinicalTrials.gov